Visceral leishmaniasis after kidney transplantation: Report of a new case and a review of the literature

被引:21
作者
Bouchekoua, Myriam [1 ]
Trabelsi, Sonia [1 ]
Ben Abdallah, Taieb [2 ]
Khaled, Samira [1 ]
机构
[1] Charles Nicolle Hosp, Parasitol Mycol Lab, Tunis 1006, Tunisia
[2] Charles Nicolle Hosp, Dept Internal Med, Tunis 1006, Tunisia
关键词
LIPOSOMAL AMPHOTERICIN-B; DRUG-ADMINISTRATION APPROVAL; KALA-AZAR; UNEXPLAINED FEVER; RARE CAUSE; RECIPIENTS; DIAGNOSIS; PATIENT;
D O I
10.1016/j.trre.2013.10.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Visceral leishmaniasis (VL) is a parasitic disease, caused by protozoa of the genus Leishmania, transmitted by the phlebotomies sand fly. In the last 20 years, the increasing frequency of organ transplantations and the improvement of associated immunosuppressive treatments have led to the recognition of several cases of VL complicating organ transplantation. Actually, less than 100 cases of VL after kidney transplantation are reported in the literature. In this context, VL is fatal without antileishmanial treatment which constitutes a difficult challenge. We report a case of VL in Tunisian renal transplant recipient treated successfully by liposomal amphotericin B (Ambisome (R), Gilead Sciences Inc). Also, we review the epidemiological, clinical, biological and therapeutic aspects of VL associated with renal transplantation reported in the literature. Our report identifies that VL should be suspected in renal transplant recipients presenting unexplained fever, splenomegaly and pancytopeny. It also suggests a serological testing for leishmaniasis in the pre-operative check-up of transplant patients and donors living or traveling in endemic areas of leishmaniasis. Moreover, recipients should be tested regularly for leishmaniasis after transplantation. Liposomal amphotericin B may be considered the treatment of choice of VL, since it has a lower incidence of side effects. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:32 / 35
页数:4
相关论文
共 51 条
[1]  
Aguado JM, 1986, CLIN TRANSPLANT, V135
[2]  
Aguado JM, 1986, J INFECT, V133, P01
[3]  
Aleya A, 2011, INDIAN J TRANSPLANT, V1, P9
[4]   Leishmaniasis among organ transplant recipients [J].
Antinori, Spinello ;
Cascio, Antonio ;
Parravicini, Carlo ;
Bianchi, Roberto ;
Corbellino, Mario .
LANCET INFECTIOUS DISEASES, 2008, 8 (03) :191-199
[5]   Current epidemiological data on visceral leishmaniasis in Tunisia [J].
Aoun, K. ;
Jeddi, F. ;
Amri, F. ;
Ghrab, J. ;
Bouratbine, A. .
MEDECINE ET MALADIES INFECTIEUSES, 2009, 39 (10) :775-779
[6]   Visceral leishmaniasis in organ transplant recipients: 11 new cases and a review of the literature [J].
Basset, D ;
Faraut, F ;
Marty, P ;
Dereure, J ;
Rosenthal, E ;
Mary, C ;
Pratlong, F ;
Lachaud, L ;
Bastien, P ;
Dedet, JP .
MICROBES AND INFECTION, 2005, 7 (13) :1370-1375
[7]   Visceral leishmaniasis (Kala-Azar) in transplant recipients -: Case report and review [J].
Berenguer, J ;
Gómez-Campderá, F ;
Padilla, B ;
Rodríguez-Ferrero, H ;
Anaya, F ;
Moreno, S ;
Valderrábano, F .
TRANSPLANTATION, 1998, 65 (10) :1401-1404
[8]   US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis - Editorial response [J].
Berman, JD .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (01) :49-51
[9]   Liposomal amphotericin B for the treatment of visceral leishmaniasis [J].
Bern, Caryn ;
Adler-Moore, Jill ;
Berenguer, Juan ;
Boelaert, Marleen ;
den Boer, Margriet ;
Davidson, Robert N. ;
Figueras, Concepcion ;
Gradoni, Luigi ;
Kafetzis, Dimitris A. ;
Ritmeijer, Koert ;
Rosenthal, Eric ;
Royce, Catherine ;
Russo, Rosario ;
Sundar, Shyam ;
Alvar, Jorge .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (07) :917-924
[10]   Visceral leishmaniasis in renal transplant recipients: Successful treatment with liposomal amphotericin B (AmBisome) [J].
Boletis, JN ;
Pefanis, A ;
Stathakis, C ;
Helioti, H ;
Kostakis, A ;
Giamarellou, H .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (06) :1308-1309